Tag: Orchestra BioMed
BACKBEAT trial of AVIM therapy exceeds enrolment goal
Orchestra BioMed has announced that it has surpassed full enrolment in the BACKBEAT global pivotal trial, exceeding its previously announced target of 316 randomised...
Orchestra BioMed secures additional capital from funding partners
Orchestra BioMed has secured US$70 million in new capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage partnered cardiology programmes—arterioventricular interval modulation (AVIM)...